Financial Position - As of September 30, 2023, the company reported an accumulated deficit of $269.0 million, cash and cash equivalents of $10.6 million, and short-term investments of $5.1 million[29]. - As of September 30, 2023, the company had total assets at fair value of $13.761 million, including cash equivalents and short-term investments[45]. - The fair value of total investment securities as of September 30, 2023, was $13,761,000, a decrease of 26.6% from $18,620,000 on December 31, 2022[47]. - The company anticipates that its existing cash and investments will not be sufficient to meet its cash requirements for at least the next 12-18 months, raising substantial doubt about its ability to continue as a going concern[30]. Operational Performance - For the nine months ended September 30, 2023, the company incurred net losses of $11.1 million and net cash used in operations of $11.1 million[29]. - The net loss from discontinued operations for the three months ended September 30, 2023, was $83,000, compared to a loss of $589,000 for the same period in 2022[35]. - The Company recorded inventory write-downs of $252,000 and $444,000 for the three and nine months ended September 30, 2023, respectively[37]. - Total inventories as of September 30, 2023, amounted to $4.281 million, an increase from $3.088 million as of December 31, 2022[38]. Financing Activities - The Company raised $6.0 million in gross proceeds from the March 2023 Private Placement, which included the issuance of 165,500 shares of common stock and various preferred investment options[61]. - The Company has a shelf Registration Statement allowing for aggregate offering prices of up to $50.0 million, effective until May 12, 2025[66]. - The Company incurred additional offering costs of $548,000 related to the March 2023 Private Placement, with $212,000 attributed to the Placement Agent Options[65]. - The August 2022 Registered Direct Offering generated total gross proceeds of $5.0 million, including the sale of 61,250 registered shares and pre-funded warrants[67]. Liabilities and Contingencies - The Company recorded a contingent liability related to the Anawah acquisition, which is measured using unobservable inputs regarding the pursuit of specific products[48][49]. - The Company has a contingent liability of $2.0 million related to the Anawah acquisition, reflecting ongoing development programs using acquired technology[93]. - As of September 30, 2023, the Company’s Level 3 liabilities included $3,836,000, down from $2,806,000 as of December 31, 2022, reflecting changes in fair value and other adjustments[52]. Stock and Compensation - The Company recognized $162,000 and $573,000 of compensation expense for stock options awards during the three and nine months ended September 30, 2023, respectively[85]. - As of September 30, 2023, there was $833,000 of unrecognized compensation cost related to unvested stock-based compensation grants, expected to be recognized over a weighted-average remaining period of 2.0 years[81]. - The Company has 84,058 options outstanding under its stock incentive plans as of September 30, 2023, with a weighted average exercise price of $82.71[80]. - The Company recorded $7,000 and $12,000 of Employee Stock Purchase Plan (ESPP) related compensation expense during the three and nine months ended September 30, 2023, respectively[86]. Lease and Asset Management - The weighted-average remaining lease term as of September 30, 2023, was 1.9 years, with a weighted-average discount rate of 6.4%[60]. - The Company’s operating lease liabilities totaled $1,271,000 as of September 30, 2023, down from $2,017,000 on December 31, 2022[60]. - Property and equipment, net, decreased to $468,000 as of September 30, 2023, from $680,000 as of December 31, 2022[39]. Research and Development - The Company accounts for research and development costs as expenses incurred, with no guarantee of technological or commercial success in collaborative arrangements[58]. - The Company has entered into contract research agreements with initial terms ranging from one to three years, which may require certain funding commitments[95]. Taxation - The effective tax rate for the Company was 0.00% for each of the three and nine months ended September 30, 2023 and 2022, primarily due to a full valuation allowance on net deferred tax assets[88]. Subsequent Events - Management has evaluated subsequent events through November 9, 2023, the date the financial statements were available to be issued[102].

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants T.J. Schaefer - Chief Financial Officer Stan Jacot - President and Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Dipesh Patel - H.C. Wainwright Operator Good afternoon, and welcome to Arcadia Biosciences' Second Quarter 2023 Financial Results and Business Highlights Conference Call. At this time, all participants are in a listen-only mode. A ...

For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 5950 S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporat ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants T.J. Schaefer - Chief Financial Officer Stan Jacot - President and Chief Executive Officer Conference Call Participants Dipesh Patel - H.C. Wainwright Ben Klieve - Lake Street Capital Markets Operator Good afternoon, and welcome to Arcadia Biosciences' First Quarter 2023 Financial Results and Business Highlights Conference Call. At this time all participants are in a listen-only mode. After ...

Financial Data and Key Metrics Changes - In Q4, total revenues were $1 million, down $877,000 from the previous quarter, primarily due to seasonality in Zola and distribution losses in both Zola and SoulSpring [52] - For the full year 2022, total revenues were approximately $10 million, an increase of $3.2 million or 47% compared to 2021 [53] - The reported loss from operations was $18.8 million, which is $16.7 million or 47% lower than the prior year [27] - Cash used in operations declined significantly from $25.9 million in 2021 to $14 million in 2022 [14][79] Business Line Data and Key Metrics Changes - GoodWheat pasta experienced significant distribution gains, with store count increasing 34% in Q4, adding more than 1,200 stores in seven months [43] - Zola sales declined in Q4 compared to the same period last year, but for the full year, Zola gained market share with a 12% increase in sales [19] - The body care segment faced challenges, with SoulSpring losing more than half of its distribution due to retailer decisions [21] Market Data and Key Metrics Changes - The pasta category saw unit sales increase by 3% and dollar sales rise by 25% in the last three months of 2022, leading to category sales of $2.9 billion [15] - The coconut water category experienced a 4% decline in units but a 10% increase in dollars for the 13 weeks ending December 24, driven by pricing [46] Company Strategy and Development Direction - The company is focused on Project Greenfield, a three-year plan aimed at unlocking potential and creating shareholder value [10] - Key strategies include establishing GoodWheat footholds in retail categories, driving share growth in key brands, and building an agile organization [38][12] - The company plans to continue investing in marketing for GoodWheat while keeping SG&A expenses relatively flat [54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the prospects for Zola moving forward, citing improvements in freight costs and plans for packaging refresh and innovation [47] - The company is ahead of its three-year path to profitability outlined in Project Greenfield, with improvements in gross profit and operating expense reductions [63] - Management acknowledged challenges in the CBD category due to retailer restrictions and marketing limitations [48] Other Important Information - The company executed a reverse stock split to avoid delisting from NASDAQ and raised additional capital to support future growth [50][23] - The company ended 2022 with $20.6 million in cash and cash equivalents, positioning it well to fund Project Greenfield beyond 2023 [79][58] Q&A Session Summary Question: When will the impact from GoodWheat retail footprint expansion be seen? - Management expects to see meaningful sales impact in the second half of 2023 [59] Question: What are the plans for coconut water and body care product lines? - Zola is seen as having strong growth prospects, while body care is under review for strategic alternatives [60] Question: What is the status of the legacy Hemp business? - The legacy business has been written down, and efforts will continue to sell remaining inventory [62] Question: When does the company expect to reach profitability? - The company is ahead of its three-year profitability plan initiated in June 2022 [63] Question: Can you elaborate on GoodWheat's performance from Q3 to Q4? - GoodWheat sales were impacted by a slowdown in new store count growth in Q4 [68] Question: What is the outlook for distribution losses in Zola? - Some distribution losses may be recoverable, while others are considered permanent [70]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37383 Arcadia Biosciences, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of ...

Arcadia Biosciences Inc (NASDAQ:RKDA) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Stan Jacot - President and Executive Officer Pam Haley - Chief Financial Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Dipesh Patel - H.C. Wainwright Operator Good afternoon, and welcome to the Arcadia Biosciences Third Quarter 2022 Earnings Conference Call. Today's presenters will be Stan Jacot, President and Chief Executive Officer; and Pam Haley, Chief F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0571538 (State or other ju ...

Arcadia Biosciences Inc (NASDAQ:RKDA) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Stan Jacot - President and Executive Officer Pam Haley - Chief Financial Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Brian Wright - ROTH Capital Partners Operator Good afternoon, and welcome to the Arcadia Biosciences Second Quarter 2022 Earnings Conference Call. Today's presenters will be Stan Jacot, President and Executive Officer; and Pam Haley, Chief Fi ...